Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential

Akero Therapeutics (AKRO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on the stock and has a $84.00 price target.

Michael Ulz’s rating is based on the promising position of Akero Therapeutics’ EFX in the MASH treatment landscape. MASH, a severe form of liver disease, affects a significant patient population with limited treatment options, presenting a substantial market opportunity. Akero’s EFX is seen as having best-in-class potential for patients with advanced fibrosis (F2/F3) and offers groundbreaking data for the more challenging F4 stage.
The upcoming Phase 3 SYNCHRONY trials, expected to begin reporting results in the first half of 2026, are anticipated to further validate EFX’s efficacy and safety. Despite the competitive landscape, EFX’s potential to address the high unmet need in MASH could drive significant sales, estimated to peak at approximately $5 billion. These factors contribute to the Buy rating, reflecting confidence in Akero’s strategic positioning and future growth prospects.

In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $64.00 price target.

Based on the recent corporate insider activity of 121 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKRO in relation to earlier this year.